Treatment(s) already received-Chemotherapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Chemotherapy Posts on Medivizor

Consolidation chemotherapy before surgery improves the outcomes in advanced rectal cancer.

Posted by on Mar 29, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of consolidation chemotherapy after initial treatment in locally advanced rectal cancer. Researchers suggested that this treatment is safe and is associated with improved cancer outcomes.  Some background Colorectal cancer is the fifth most common cancer. From all the colorectal...

Read More

The use of brentuximab vedotin before transplant for patients with Hodgkin’s lymphoma

Posted by on Mar 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes for patients with Hodgkin’s lymphoma who received brentuximab vedotin (Adcetris) compared to chemotherapy before a stem cell transplant. This study concluded that patients who received brentuximab vedotin had a better survival. Some background Allogeneic hematopoietic stem cell...

Read More

Does bone Hodgkin lymphoma affect survival in patients with Hodgkin lymphoma?

Posted by on Feb 19, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated if patients with Hodgkin lymphoma (HL) found in the bones have worse outcomes than patients with HL in the lymph nodes. It was found that having bone HL did not reduce survival of patients. Some background Many patients with HL are cured by treatment. After 5 years, almost 86% of patients survive. When...

Read More

Is stem cell transplant more effective than other treatments for multiple myeloma?

Posted by on Feb 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effects of stem cell transplant to other newer treatments for recently diagnosed multiple myeloma (MM). The main finding was patients who received stem cell transplant had better outcomes than those who did not. Some background Stem cell transplant involves the transfer of cells to a patient. This is an effective...

Read More

Evaluating second-line rituximab-bendamustine treatment for patients with follicular lymphoma

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...

Read More

Evaluating the use of PET scanning after first-line treatment for follicular lymphoma

Posted by on Nov 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the value of PET (positron emission tomography) scanning after first-line (primary) chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL). This study concluded that PET scanning is a better imaging technique than CT (computed tomography) for assessing treatment response in these...

Read More

Cognitive performance is affected by chemotherapy in patients with colorectal cancer

Posted by on Oct 20, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effects of chemotherapy after surgery on cognitive performance (CP; attention, memory and thinking processes) in patients with colorectal cancer. Researchers suggested that patients who received chemotherapy after surgery had a decreased CP. Some background Surgery followed by chemotherapy is the standard...

Read More

Evaluating Zevalin followed by stem cell transplantation for relapsed or refractory NHL

Posted by on Oct 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...

Read More